Freenome to Participate in the Piper Sandler 38th Annual Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Freenome (NASDAQ: FRNM) management will participate in the Piper Sandler 38th Annual Healthcare Conference on December 1, 2026.
The fireside chat is scheduled for 4:30pm to 4:55pm Eastern Time. A live and archived webcast will be available in the Events section of Freenome’s investor relations website.
Key Terms
cell-free dna technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (NASDAQ: FRNM), a personalized cancer detection company using an AI-driven multiomics platform to develop and optimize single- and multi-cancer blood tests, today announced company management will participate in the Piper Sandler 38th Annual Healthcare Conference.
Management will participate in a fireside chat from 4:30pm to 4:55pm Eastern Time on Tuesday, Dec. 1, 2026.
A live and archived webcast of the events will be available on the “Events” section of the Freenome investor relations website at https://investors.freenome.com/news-events/events.
About Freenome
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company’s proprietary AI-driven multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome’s development of FDA-approved SimpleScreen CRC for colorectal cancer screening and a pipeline of tests for lung cancer and additional single- and multi-cancer indications is designed to increase cancer screening participation among millions of at-risk individuals.
Freenome Contacts:
Investor Relations
Gilmartin Group LLC
investor-relations@freenome.com
Media Contact
Ryan Flinn
The Grace Group
ryan@gracegroup.us
media@gracegroup.us